Evidence map›Paper›PMID 37464380›Full record

ArticleCell & bioscience2023

Multiple Fra-1-bound enhancers showing different molecular and functional features can cooperate to repress gene transcription.

Fabienne Bejjani, Emilie Evanno, Samantha Mahfoud, Claire Tolza, Kazem Zibara, Marc Piechaczyk, Isabelle Jariel-Encontre

Open access · goldAbstract read
In one paragraph

Article in Cell & bioscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Fabienne Bejjani *IGMM, Univ Montpellier, CNRS, Montpellier, France.
Emilie Evanno *IGMM, Univ Montpellier, CNRS, Montpellier, France.
Samantha Mahfoud *IGMM, Univ Montpellier, CNRS, Montpellier, France.
Claire Tolza *IGMM, Univ Montpellier, CNRS, Montpellier, France.
Kazem ZibaraDSST, ER045, PRASE, Lebanese University, Beirut, Lebanon.
Marc Piechaczyk *IGMM, Univ Montpellier, CNRS, Montpellier, France.
Isabelle Jariel-Encontre *IGMM, Univ Montpellier, CNRS, Montpellier, France. isabelle.jariel@inserm.fr.ORCID http://orcid.org/0000-0002-5769-9233
Centre National de la Recherche Scientifique · FRLebanese University · LB

Funding

Cancéropôle Grand Ouest 2017-E08Ligue Contre le Cancer 192376Ligue Contre le Cancer Equipe Labellisée EL2019
6 · The paper itself

Abstract

backgroundHow transcription factors (TFs) down-regulate gene expression remains ill-understood, especially when they bind to multiple enhancers contacting the same gene promoter. In particular, it is not known whether they exert similar or significantly different molecular effects at these enhancers.

resultsTo address this issue, we used a particularly well-suited study model consisting of the down-regulation of the TGFB2 gene by the TF Fra-1 in Fra-1-overexpressing cancer cells, as Fra-1 binds to multiple enhancers interacting with the TGFB2 promoter. We show that Fra-1 does not repress TGFB2 transcription via reducing RNA Pol II recruitment at the gene promoter but by decreasing the formation of its transcription-initiating form. This is associated with complex long-range chromatin interactions implicating multiple molecularly and functionally heterogeneous Fra-1-bound transcriptional enhancers distal to the TGFB2 transcriptional start site. In particular, the latter display differential requirements upon the presence and the activity of the lysine acetyltransferase p300/CBP. Furthermore, the final transcriptional output of the TGFB2 gene seems to depend on a balance between the positive and negative effects of Fra-1 at these enhancers.

conclusionOur work unveils complex molecular mechanisms underlying the repressive actions of Fra-1 on TGFB2 gene expression. This has consequences for our general understanding of the functioning of the ubiquitous transcriptional complex AP-1, of which Fra-1 is the most documented component for prooncogenic activities. In addition, it raises the general question of the heterogeneity of the molecular functions of TFs binding to different enhancers regulating the same gene.

Indexed as

AP-1CBPEnhancerFOSL1Fra-1p300TranscriptionTranscription repressionTriple negative breast cancer

Identifiers

PMID37464380
PMCPMC10354941
OpenAlexW4384663339

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.